{"id":"abm-1310","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{"Pregnancy":"null","Paediatric use":"null","Renal impairment":"null","Hepatic impairment":"null"},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT05892653","NCT05501912","NCT04190628"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2024","type":"negative","milestone":"Phase 1 Initiated","description":"Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors — Advanced Solid Tumor. Trial terminated early."}],"aiSummary":"ABM-1310 is an investigational targeted therapy evaluated in Phase 1 trials for advanced solid tumors and BRAF V600-mutant cancers. It is being studied for its safety and tolerability in small patient cohorts, with no approved indications yet.","brandName":"ABM-1310","companyId":"unknown","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"ABM-1310 is an investigational drug currently being studied in early-stage clinical trials. It is being tested in patients with advanced solid tumors and those with BRAF V600-mutant cancers, including cases that have relapsed or become resistant to other treatments. The drug is in the Phase 1 stage, which means researchers are primarily focused on understanding its safety and how well it is tolerated by patients. At this point, it is not approved for any specific use and is still under evaluation.","oneSentence":"ABM-1310 is an experimental cancer drug tested in early trials for advanced tumors and BRAF-mutant cancers.","technicalDetail":"ABM-1310 is an investigational targeted therapy being evaluated in Phase 1 clinical trials for advanced solid tumors and BRAF V600-mutant cancers. The trials include cohorts of patients with relapsed or drug-resistant malignancies, as well as those with advanced solid tumors. The drug's molecular targets and specific pathway mechanisms are not detailed in the provided data, but its development is focused on cancers with BRAF V600 mutations."},"commercial":null,"references":[],"biosimilars":[],"companyName":"","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"ABM-1310","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05892653","phase":"Phase 1","title":"A Phase I, Open-Label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics &Preliminary Anti-Cancer Efficacy of ABM-1310 in Patients With BRAF V600-Mutant Relapsed &Drug ","status":"TERMINATED","sponsor":"ABM Therapeutics Shanghai Company Limited","isPivotal":false,"enrollment":15,"indication":"Primary Malignant Brain Tumor","completionDate":"2024-08-27"},{"nctId":"NCT05501912","phase":"Phase 1","title":"A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Cancer Activity of ABM-1310 in Patients With BRAF V","status":"TERMINATED","sponsor":"ABM Therapeutics Shanghai Company Limited","isPivotal":false,"enrollment":20,"indication":"Advanced Solid Tumor, BRAF V600 Mutation","completionDate":"2024-06-17"},{"nctId":"NCT04190628","phase":"Phase 1","title":"A Phase I, First-In-Human, Multicenter, Open-Label Dose Escalation and Dose Expansion Study of ABM-1310, as a Monotherapy and a Combination Therapy, Administered Orally in Adult Patients With Advanced","status":"TERMINATED","sponsor":"ABM Therapeutics Corporation","isPivotal":false,"enrollment":53,"indication":"Advanced Solid Tumor, BRAF V600 Mutation","completionDate":"2024-04-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}